Zafgen Inc. (NASDAQ:ZFGN) shares were up 3% during mid-day trading on Thursday . The stock traded as high as $6.48 and last traded at $6.44, with a volume of 219,670 shares traded. The stock had previously closed at $6.25.

Several research analysts recently issued reports on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Thursday, May 12th. FBR & Co reissued a “buy” rating and set a $20.00 price objective on shares of Zafgen in a report on Friday, March 11th. Royal Bank Of Canada dropped their price objective on Zafgen from $21.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, March 10th. Leerink Swann reissued a “market perform” rating and set a $6.00 price objective on shares of Zafgen in a report on Thursday, March 17th. Finally, Canaccord Genuity cut Zafgen from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $30.00 to $7.00 in a report on Thursday, March 10th. Four investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $11.94.

The company’s market capitalization is $175.63 million. The company’s 50 day moving average price is $6.45 and its 200 day moving average price is $6.58.

Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. During the same period in the prior year, the firm posted ($0.53) earnings per share. Equities analysts predict that Zafgen Inc. will post ($2.81) earnings per share for the current year.

An institutional investor recently bought a new position in Zafgen stock. Oxford Asset Management acquired a new stake in shares of Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, Holdings Channel reports. The firm acquired 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned 0.87% of Zafgen as of its most recent SEC filing.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.